to wide confidence intervals

Odds ratios become unstable with small cell counts in 2×2 tables

Power is directly tied to exposure prevalence—not just sample size

Solution:

Increase sample size substantially or pool data from multiple sources such as national health databases, claims records, and GMP audit checklists to capture more exposed individuals.

Limitation 2: Exposure Misclassification

Rare exposures are often less documented, especially if they occur outside standard care pathways. Inaccuracies arise due to:

• Incomplete EHR or pharmacy records
• Patient recall errors (especially in retrospective settings)
• Lack of standardized coding for rare interventions

Solution:

• Use multiple data sources to triangulate exposure
• Incorporate drug barcoding, lab monitoring, or specialty pharmacy logs
• Clearly define exposure windows and minimum dosage thresholds

These practices are emphasized in pharma SOP documentation for study data integrity.

Limitation 3: Selection Bias and Control Matching Difficulties

When exposure is rare, finding unexposed controls with similar characteristics becomes challenging. Matching may inadvertently introduce bias or lead to overmatching, diluting the true exposure effect.

Example: In a study assessing a rare antineoplastic agent, all suitable controls may be from populations with vastly different disease risks or healthcare access patterns.

Solution:

• Consider using incidence-density sampling
• Utilize a nested case-control design within a defined cohort
• Avoid excessive matching variables unless justified

Limitation 4: Confounding by Indication and Channeling Bias

Patients receiving rare therapies often differ systematically from those who don’t. These differences (e.g., disease severity, comorbidities) confound the exposure-outcome relationship.

Example: Patients receiving compassionate-use treatments are often in advanced disease stages, skewing outcome comparisons.

Solution:

• Collect detailed clinical data and adjust via logistic regression or propensity scores
• Use instrumental variable methods where applicable
• Document all confounding assumptions as part of validation master plans

Limitation 5: Temporal Ambiguity

Rare exposures may be transient or occur near disease onset, making it unclear whether the exposure preceded or followed the disease process.

Solution:

• Establish strict exposure windows (e.g., exclude exposures within 6 months of diagnosis)
• Use pharmacy fill dates and clinical notes to verify timelines
• Cross-reference with diagnostic milestone events

Limitation 6: Difficulty Capturing Over-the-Counter or Non-Systemic Exposures

Rare exposures such as herbal supplements, compounded medications, or occupational chemicals are often poorly captured in administrative datasets.

Solution:

• Use structured interviews or electronic patient-reported outcomes (ePROs)
• Incorporate job-exposure matrices (JEMs) for occupational studies
• Link registries with survey instruments or specialty provider networks

Alternative Study Designs to Consider:

1. Cohort Studies: Suitable when exposure is well-documented and rare
2. Self-Controlled Case Series (SCCS): Useful for transient exposures with acute outcomes
3. Case-Crossover Studies: Effective when assessing exposures that vary over time (e.g., drug-drug interactions)

Regulatory Expectations and RWE Integration:

Global regulatory bodies like CDSCO and EMA recommend that rare exposure assessments be conducted transparently, with clear documentation of limitations and mitigation strategies.

Studies relying on case-control methods must:

• Declare limitations in power and generalizability
• Include sensitivity analyses with alternate exposure definitions
• Submit exposure classification logic for audit or replication

Adherence to such expectations is crucial for generating pharmaceutical compliance in observational study submissions.

Checklist for Pharma Professionals Designing Case-Control Studies on Rare Exposures:

• ☑ Confirm that exposure prevalence is sufficient for analysis
• ☑ Use multi-database strategies to identify exposed subjects
• ☑ Pre-define exposure criteria and data sources
• ☑ Minimize recall and measurement bias through EHR linkage
• ☑ Select controls from the same risk pool to reduce bias
• ☑ Clearly report assumptions, biases, and sensitivity analyses

Conclusion: Addressing the Limits of Case-Control Design for Rare Exposure Studies

While case-control studies offer valuable insights, their application to rare exposure assessment demands caution. Limitations in power, exposure misclassification, and selection bias must be actively addressed through thoughtful design and methodological rigor. By applying these mitigation strategies, pharma professionals can enhance the reliability of their findings, meet global regulatory standards, and support better decision-making based on real-world data.

Ultimately, a transparent, well-documented case-control study—backed by comprehensive GMP validation and sound epidemiological principles—can still yield actionable insights, even in the most challenging rare exposure scenarios.